{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:53:05Z","timestamp":1775872385092,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,26]]},"DOI":"10.7759\/cureus.104281","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:38:30Z","timestamp":1772105910000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia"],"prefix":"10.7759","author":[{"given":"Kelvin","family":"Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshia","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman J","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurdeep H","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023, 402:203-34. 10.1016\/s0140-6736(23)01301-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun H","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022, 183:109119. 10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1515797","article-title":"Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the Global Burden of Disease Study 2021","volume":"13","author":"Huang X","year":"2025","unstructured":"Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the Global Burden of Disease Study 2021. Front Public Health. 2025, 13:1515797. 10.3389\/fpubh.2025.1515797","journal-title":"Front Public Health"},{"key":"ref4","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017-2018","volume":"360","author":"Hales CM","year":"2020","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020, 360:1-8.","journal-title":"NCHS Data Brief"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.13.1581","article-title":"Impact of overweight on the risk of developing common chronic diseases during a 10-year period","volume":"161","author":"Field AE","year":"2001","unstructured":"Field AE, Coakley EH, Must A, et al.. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001, 161:1581-6. 10.1001\/archinte.161.13.1581","journal-title":"Arch Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01624-4","article-title":"Tirzepatide: a double agonist for various people living with type 2 diabetes","volume":"15","author":"Strollo F","year":"2024","unstructured":"Strollo F, Guarino G, Satta E, Gentile S. Tirzepatide: a double agonist for various people living with type 2 diabetes. Diabetes Ther. 2024, 15:1855-60. 10.1007\/s13300-024-01624-4","journal-title":"Diabetes Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/s0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021, 398:1811-24. 10.1016\/s0140-6736(21)02188-7","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik B","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398:583-98. 10.1016\/s0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1397029","article-title":"A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database","volume":"15","author":"Liu L","year":"2024","unstructured":"Liu L. A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2024, 15:1397029. 10.3389\/fphar.2024.1397029","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.21307\/immunohematology-2019-099","article-title":"Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms","volume":"30","author":"Curtis BR","year":"2014","unstructured":"Curtis BR. Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology. 2014, 30:55-65.","journal-title":"Immunohematology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"Aster RH","year":"2009","unstructured":"Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009, 7:911-8. 10.1111\/j.1538-7836.2009.03360.x","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker A","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, et al.. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018, 2:3360-92. 10.1182\/bloodadvances.2018024489","journal-title":"Blood Adv"},{"key":"ref15","article-title":"Drug-induced immune thrombocytopenia","author":"Arnold DM","year":"2025","unstructured":"Arnold DM, Cuker A. Drug-induced immune thrombocytopenia. UpToDate. Connor RF (ed): UpToDate, Waltham, MA; 2025."},{"key":"ref16","unstructured":"Mounjaro mediated drug-induced immune thrombocytopenia. (2024). https.\/\/scholarlyworks.corewellhealth.org\/cgi\/viewcontent.cgi?article=1040&context=internal_medicine_posters."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas MK","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:388-96. 10.1210\/clinem\/dgaa863","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng Z","year":"2023","unstructured":"Meng Z, Yang M, Wen H, Zhou S, Xiong C, Wang Y. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. Front Endocrinol (Lausanne). 2023, 14:1121387. 10.3389\/fendo.2023.1121387","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra R","year":"2023","unstructured":"Mishra R, Raj R, Elshimy G, et al.. Adverse events related to tirzepatide. J Endocr Soc. 2023, 7:bvad016. 10.1210\/jendso\/bvad016","journal-title":"J Endocr Soc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-009803","article-title":"Patients with quinine-induced immune thrombocytopenia have both \"drug-dependent\" and \"drug-specific\" antibodies","volume":"108","author":"Bougie DW","year":"2006","unstructured":"Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both \"drug-dependent\" and \"drug-specific\" antibodies. Blood. 2006, 108:922-7. 10.1182\/blood-2006-01-009803","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462549-a-rare-case-of-tirzepatide-associated-immune-thrombocytopenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:38:31Z","timestamp":1772105911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462549-a-rare-case-of-tirzepatide-associated-immune-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.104281","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}